Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.

Second, although the analysis of negative control outcomes showed a marginally significant association between semaglutide 2.4 mg use and sensorineural hearing loss (HR: 1.09, 95% CI: 1.01–1.17; p < 0.05), the effect size is small and above 1, suggesting that even if weak residual confounding exists in the current study, it would likely bias our findings from the main analyses conservatively toward the null.

also in 26,082 other papers